TransMedics Group, Inc. (TMDX)
Automate Your Wheel Strategy on TMDX
With Tiblio's Option Bot, you can configure your own wheel strategy including TMDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TMDX
- Rev/Share 16.6026
- Book/Share 10.4126
- PB 11.754
- Debt/Equity 1.3084
- CurrentRatio 7.6893
- ROIC 0.1054
- MktCap 4182592577.0
- FreeCF/Share 3.5367
- PFCF 34.668
- PE 45.4969
- Debt/Assets 0.4913
- DivYield 0
- ROE 0.3142
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | TMDX | Needham | Hold | Buy | -- | $148 | Oct. 23, 2025 |
| Initiation | TMDX | Jefferies | -- | Buy | -- | $145 | Oct. 13, 2025 |
| Initiation | TMDX | Evercore ISI | -- | Outperform | -- | $155 | Sept. 16, 2025 |
| Initiation | TMDX | Stifel | -- | Hold | -- | $115 | Sept. 4, 2025 |
| Downgrade | TMDX | JP Morgan | Overweight | Neutral | $116 | $75 | Dec. 17, 2024 |
| Initiation | TMDX | Robert W. Baird | -- | Outperform | -- | $200 | Sept. 24, 2024 |
| Initiation | TMDX | Needham | -- | Buy | -- | $208 | Aug. 21, 2024 |
News
TransMedics: Growth Tailwinds Should Provide Upside In 2026
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on international expansion, will be supportive of growth going forward. While TransMedics faces margin headwinds in the short term, profitability continues to improve and will be supportive of the company's valuation in the long term.
Read More
TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.
Read More
TransMedics: Q3 Results Disappointed, As Expected (Rating Upgrade)
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuation attractive and expectations more reasonable. Industry data signals a strong Q4 ahead, supporting the case for near-term upside in TMDX.
Read More
TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
TMDX Partners With Mercedes-Benz to Launch Organ Transport Network
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics collaborates with Mercedes-Benz to launch Italy's first organ transport network, expanding its OCS model beyond the United States.
Read More
Here's Why TransMedics (TMDX) is a Strong Growth Stock
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
TransMedics: I'm More Bullish Than Ever
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics remains a strong buy despite recent pullback, driven by seasonal weakness and changing transplant transport trends. TMDX's next-gen OCS heart and lung devices, along with kidney perfusion development, position TMDX for significant growth and market expansion. International markets, especially Europe, Middle East, and Australia, offer substantial growth opportunities and diversification beyond the US core business.
Read More
Why TransMedics (TMDX) is a Top Momentum Stock for the Long-Term
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
TransMedics Group, Inc. (TMDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
TransMedics Group, Inc. (NASDAQ:TMDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Hi, everybody. Welcome and thanks for joining.
Read More
TransMedics: Just Like The CEO, I'm Buying
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics remains a Strong Buy after stellar growth, innovative technology, and founder-led leadership, with shares up 88% YTD, far outpacing the S&P 500. The company's unique OCS platform, integrated logistics, and service model create a strong moat, with next-gen products and international expansion as major growth catalysts. Financials are robust: Q2 2025 revenue grew 37.7% YoY, margins improved, and guidance was raised.
Read More
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Read More
Why Is TransMedics (TMDX) Down 1.9% Since Last Earnings Report?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Negative
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why TransMedics (TMDX) is a Strong Momentum Stock
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why TransMedics (TMDX) is a Strong Growth Stock
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX broke out above the 50-day moving average, suggesting a short-term bullish trend.
Read More
Why TransMedics (TMDX) is a Top Momentum Stock for the Long-Term
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why TransMedics (TMDX) is a Top Growth Stock for the Long-Term
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
Read More
Live Earnings: Will TransMedics (TMDX) Rally After Earnings?
Published: July 30, 2025 by: 24/7 Wall Street
Sentiment: Neutral
TransMedics Group reports its Q2 earnings after the bell. Wall Street current expectations stand at: Revenue: $147.74 million Adjusted EPS: $.43 We'll be updating this live blog with updates during the trading day and then once earnings hit the newswires will post a flurry of news and analysis.
Read More
Why TransMedics Remains A Buy Into 2026
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics beat Q1 2025 estimates and raised full-year guidance, showing strong revenue and earnings growth. The company holds a unique market position with the only FDA-approved system for heart, lung, and liver transport. Profitability and margins are improving, though free cash flow, dilution, and a limited TAM remain concerns.
Read More
TransMedics: Q2 Analyst Estimates Will Fall Short
Published: July 14, 2025 by: Seeking Alpha
Sentiment: Neutral
TransMedics has rebounded from a sharp sell-off by consistently beating guidance and demonstrating strong execution, restoring investor confidence. I anticipate Q2 2025 will deliver another earnings beat, with flight activity data suggesting sales could surpass analyst estimates. The company is showing clear operating leverage, manageable debt, and is building a vertically integrated logistics network in a niche market.
Read More
Is TransMedics Stock a Buy After Short-Seller Drama?
Published: July 03, 2025 by: The Motley Fool
Sentiment: Positive
Explore the exciting world of TransMedics (TMDX 0.97%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Read More
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
TransMedics Group, Inc. (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach Out
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Read More
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Read More
TransMedics: Extremely Undervalued And Extremely Innovative
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
TransMedics delivered a stellar Q1, beating revenue and EPS estimates, and raised FY25 guidance, showcasing robust growth and execution. I see significant upside from expanding organ utilization, especially with the upcoming kidney market and international opportunities, which meaningfully increase TAM. Despite risks like share dilution, logistics complexity, and regulatory hurdles, TMDX's moat and growth trajectory remain compelling.
Read More
About TransMedics Group, Inc. (TMDX)
- IPO Date 2019-05-02
- Website https://www.transmedics.com
- Industry Medical - Devices
- CEO Waleed H. Hassanein
- Employees 728